Abstract:Immune checkpoint inhibitors (ICIs), Ipilimumab, Nivolumab, Pembrolizumab and Atezolizumab, have been applied in anti-tumor therapy and demonstrated exciting performance compared to conventional treatments. However, the unsatisfactory response rates, high recurrence and adaptive resistance limit their benefits. Metabolic reprogramming appears to be one of the crucial barriers to immunotherapy. The deprivation of required nutrients and altered metabolites not only promote tumor progression but also confer dysfunction on immune cells in the tumor microenvironment (TME). Glycolysis plays a central role in metabolic reprogramming and immunoregulation in the TME, and many therapies targeting glycolysis have been developed, and their combinations with ICIs are in preclinical and clinical trials. Additional attention has been paid to the role of amino acids, lipids, nucleotides and mitochondrial biogenesis in metabolic reprogramming and clinical anti-tumor therapy. This review attempts to describe reprogramming metabolisms within tumor cells and immune cells, from the aspects of glycolysis, amino acid metabolism, lipid metabolism, nucleotide metabolism and mitochondrial biogenesis and their impact on immunity in the TME, as well as the significance of targeting metabolism in anti-tumor therapy, especially in combination with ICIs. In particular, we highlight the expression mechanism of programmed cell death (ligand) 1 [PD-(L)1] in tumor cells and immune cells under reprogramming metabolism, and discuss in detail the potential of targeting key metabolic pathways to break resistance and improve the efficacy of ICIs based on results from current preclinical and clinical trials. Besides, we draw out biomarkers of potential predictive value in ICIs treatment from a metabolic perspective.

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer

Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints

Targeting T-cell metabolism to boost immune checkpoint inhibitor therapy

Tumor Immune Checkpoints and Their Associated Inhibitors

Immunometabolism: a new dimension in immunotherapy resistance

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Immune Checkpoint Inhibitor-Based Strategies For Synergistic Cancer Therapy

Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment

Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies

Metabolic Checkpoints and Novel Approaches for Immunotherapy Against Cancer

Metabolic Crosstalk in the Tumor Microenvironment Regulates Antitumor Immunosuppression and Immunotherapy Resisitance.

Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

Mechanisms of Tumor Resistance to Immune Checkpoint Blockade and Combination Strategies to Overcome Resistance

Immuno-Metabolism: The Role of Cancer Niche in Immune Checkpoint Inhibitor Resistance

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Metabolic interventions: A new insight into the cancer immunotherapy

Metabolic Implications of Immune Checkpoint Proteins in Cancer

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials